Takara Bio Inc. announced the mid-term management plan from April 2012 to March 2015.


At Takara Bio, “contributing to the health of mankind through the development of revolutionary biotechnologies such as gene therapy” is our corporate philosophy.Takara Bio works to expand its Genetic engineering research business, which underpins stable earnings, to nurture its AgriBio business, which is positioned to become our second profitable business, and thereby to aggressively advance R&D activities of its Gene medicine Business, which is the Group’s platform for growth.


In this midterm management plan, our goal is to absorb an increase in research and development expenses, to reach record net sales of ¥23.6 billion, and to achieve an operating income of ¥1.8 billion in fiscal 2015.


In the Genetic engineering research business, the group intends to expand its business by actively providing new products and services in the real-time PCR analysis field and the advanced cell biology field-markets that promise growth. As for the AgriBio business, plans call for achieving operating income in fiscal 2013 by increasing sales of health foods and mushroom products and undertaking effective and efficient expenditure. In the Gene medicine business, we will actively promote clinical development of cell and gene therapies by utilizing our technologies and expertise we will strive to enhance our biopharmaceutical development support services , while also aiming to increase sales.

1. Profit forecasts

Consolidated Financial Forecast

(Millions of Yen)

(FY2013 ; Year ended March 31,2013)
Forecast of Consolidated Net Sales by Business Segment

(Millions of Yen)

Forecast of Operating Profit / Loss by Business Segment

(Millions of Yen)

Forecast of R&D Expenses by Business Segment

(Millions of Yen)

2. Strategy by each segment

While posting continuous profits, implementing selection and concentration in the deployment of management resources, we aim to build the foundation for future growth. Focusing on our three business segments; the Genetic engineering research business, Gene medicine, and AgriBio, we will advance these areas as follows.


(1) Genetic engineering research business
This business is the Takara Bio Group’s core business and earnings base. It sells research reagents and scientific instruments used by biotechnology researchers in universities and companies worldwide, and provides contract research services. In order to further strengthen this business, we will expand our field of business from supporting basic research to drug-discovery and industry while intending to actively advance the business as follows;

  • Develop new products/increase sales in the real-time PCR analysis field and the advanced cell biology field
  • Develop technologies related to next-generation sequencing analysis and increase sales of their contract services
  • Enhance development of PCR products in the Applied fields (food product analysis, environmental analysis, and molecular diagnostics) and proactively develop our business in Asia
  • Advance development of core technologies through collaboration of Takara Bio(Japan), Clontech Laboratories(US), and China;Takara Biotechnology(Dalian)(China)
  • Pursue new alliances with companies that have technologically complementary products to our own


(2) Gene medicine business
Aiming for the commercialization of gene therapies, we promote clinical development. We will intend to enhance our biopharmaceutical development support services that utilize our technologies and expertise, while aiming to increase sales.


(Gene Therapy)

  • Advance clinical development of HSV-TK gene therapy for leukemia, targeting commercialization in FY2018
  • Advance clinical development of oncolytic virus HF10 in the U.S., targeting commercialization in FY2019
  • Advance clinical development of HIV gene therapy in the U.S. that uses MazF endoribonuclease, targeting commercialization in FY2023
  • Advance clinical development of TCR gene therapy for cancer, targeting to start clinical trials in FY2014
  • Expand business providing biopharmaceutical development support (such as production of vectors for gene therapy and biosafety testing services)


(Cell Therapy)

We will advance our cell therapy business as well as promote clinical development of cancer immunotherapy.

  • Advance clinical development of Natural Killer(NK) cell therapy
  • Acquire evidential data on the clinical development of RetroNectin® induced T cell therapy (RIT) and boost sales of technical support services
  • Expand revenue from cell culture media and gas-permeable bags for cell therapy


(3) AgriBio business
In relation to health food and mushrooms, mainly focusing on the development of functional food ingredients, we will actively develop the following businesses.

  • Increase BtoB sales by strengthening scientific evidence for health food ingredients based on their functional constituents, including Gagome kombu (kelp) “fucoidan,” agar-derived “agaro-oligosaccharide,” Ashitaba (angelica herb) “chalcone,” yam (dioscorea esculenta)”YamsgeninTM,” herb (peucedanum japonicum) “isosamidin,” and mushroom “terpene”
  • Advance joint research with medical academia for the purpose of acquiring basic and clinical data using functional food ingredients
  • Strengthen quality control / quality assurance systems in order to ensure the provision of safe, reliable products
  • Enhance logistics systems for and increase sales of Hatakeshimeji and Honshimeji mushrooms
  • Expand business for licensing mushroom-cultivation technology and expertise